Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells

PURPOSE: This study aimed to evaluate anticancer effects of combination treatment with poly(ADP-ribose) polymerase (PARP) and checkpoint kinase 1 (Chk1) inhibitors in BRCA wild-type ovarian cancer. PARP inhibitors can function as DNA-damaging agents in BRCA wild-type cancer, even if clinical activit...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Hye-yon, Kim, Yong-Beom, Park, Wook-ha, No, Jae Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291182/
https://www.ncbi.nlm.nih.gov/pubmed/33332934
http://dx.doi.org/10.4143/crt.2020.1013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291182/
https://www.ncbi.nlm.nih.gov/pubmed/33332934
http://dx.doi.org/10.4143/crt.2020.1013

Ejemplares similares